{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:12:34Z","timestamp":1776737554924,"version":"3.51.2"},"reference-count":34,"publisher":"Impact Journals, LLC","issue":"58","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,17]]},"DOI":"10.18632\/oncotarget.21931","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:03:18Z","timestamp":1508770998000},"page":"98757-98770","source":"Crossref","is-referenced-by-count":12,"title":["Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region"],"prefix":"10.18632","volume":"8","author":[{"given":"Shuhua","family":"Yi","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Yan","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Lv","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Yu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enbin","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengjun","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Ru","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Vardiman","year":"2008"},{"key":"2","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Menestrina","year":"2006","journal-title":"Blood"},{"key":"3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Davis","year":"2010","journal-title":"Blood"},{"key":"4","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.3324\/haematol.2014.107680","article-title":"A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders","volume":"99","author":"Traverse-Glehen","year":"2014","journal-title":"Haematologica"},{"key":"5","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1038\/bcj.2017.28","article-title":"Prevalence of hepatitis B and hepatitis C viral infections in various subtypes of B-cell non-Hodgkin lymphoma: confirmation of the association with splenic marginal zone lymphoma","volume":"7","author":"Yi","year":"2017","journal-title":"Blood Cancer J"},{"key":"6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Perez Fernandez","year":"2012","journal-title":"Br J Haematol"},{"key":"7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia","volume":"169","author":"Villa","year":"2015","journal-title":"Br J Haematol"},{"key":"8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","article-title":"Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma","volume":"93","author":"Ali","year":"2014","journal-title":"Ann Hematol"},{"key":"9","doi-asserted-by":"publisher","first-page":"E119","DOI":"10.1002\/ajh.23314","article-title":"Survival outcomes with and without splenectomy in splenic marginal zone lymphoma","volume":"87","author":"Olszewski","year":"2012","journal-title":"Am J Hematol"},{"key":"10","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Siakantaris","year":"2013","journal-title":"Oncologist"},{"key":"11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.leukres.2016.03.005","article-title":"Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era","volume":"44","author":"Pulsoni","year":"2016","journal-title":"Leuk Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","article-title":"Epidemiological serosurvey of Hepatitis B in China \u2014 Declining HBV prevalence due to Hepatitis B vaccination","volume":"27","author":"Chen","year":"2009","journal-title":"Vaccine"},{"key":"13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdl388","article-title":"Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT","volume":"18","author":"Frezzato","year":"2007","journal-title":"Ann Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12185-009-0426-y","article-title":"Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier","volume":"90","author":"Koike","year":"2009","journal-title":"Int J Hematol"},{"key":"15","first-page":"511","article-title":"Splenic marginal zone lymphoma in a patient with chronic hepatitis B","volume":"18","author":"Tsianos","year":"2009","journal-title":"J Gastrointestin Liver Dis"},{"key":"16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bcmd.2009.01.004","article-title":"Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires","volume":"42","author":"Varettoni","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"17","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2010.025437","article-title":"Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma","volume":"95","author":"Marasca","year":"2010","journal-title":"Haematologica"},{"key":"18","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% ginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implicationof patients with splenic mars","volume":"26","author":"Bosler","year":"2012","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/leu.2012.257","article-title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphomas","volume":"27","author":"Bouabdhalla","year":"2013","journal-title":"Leukemia"},{"key":"20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2141.2012.09163.x","article-title":"The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma","volume":"158","author":"Matutes","year":"2012","journal-title":"Br J Haematol"},{"key":"21","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing","volume":"21","author":"Xochelli","year":"2015","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1182\/blood.V99.4.1299","article-title":"Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course","volume":"99","author":"Algara","year":"2002","journal-title":"Blood"},{"key":"23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Govi","year":"2011","journal-title":"Blood"},{"key":"24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma","volume":"158","author":"Calasanz","year":"2012","journal-title":"Br J Haematol"},{"key":"25","first-page":"1811","article-title":"Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome","volume":"29","author":"Yiakoumis","year":"2009","journal-title":"Anticancer Research"},{"key":"26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Salar","year":"2008","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"publisher","first-page":"42362","DOI":"10.18632\/oncotarget.5705","article-title":"High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival","volume":"6","author":"Cui","year":"2015","journal-title":"Oncotarget"},{"key":"28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/gim.2016.81","article-title":"Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia","volume":"19","author":"Yu","year":"2017","journal-title":"Genet Med"},{"key":"29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3109\/10428194.2010.531411","article-title":"TOSO is overexpressed and correlated with disease progression in Chinese patients with chronic lymphocytic leukemia","volume":"52","author":"Chan","year":"2011","journal-title":"Leukemia & Lymphoma"},{"key":"30","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Rosati","year":"1982","journal-title":"JAMA"},{"key":"31","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Piris","year":"2002","journal-title":"Blood"},{"key":"32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Coiffier","year":"2002","journal-title":"Clin Lymphoma"},{"key":"33","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Brice","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients","volume":"120","author":"Catovsky","year":"2003","journal-title":"British Journal of Haematology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T14:34:20Z","timestamp":1589207660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":34,"journal-issue":{"issue":"58","published-print":{"date-parts":[[2017,11,17]]}},"alternative-id":["21931","29228725"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21931","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}